Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: Characterization of polar metabolites by chemical derivatization with dansyl chloride

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1071-1080

  Prakash, Chandra ^a   O'Donnell, John ^a   Khojasteh Bakht, S Cyrus ^a,b  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; ALKANE 1 MONOOXYGENASE; AMINE; BENZYLAMINE DERIVATIVE; DANSYL CHLORIDE; DRUG METABOLITE; EZLOPITANT; O DEMETHYLASE; PHENOL DERIVATIVE; PROPIONIC ACID; QUINUCLIDINE DERIVATIVE; SUBSTANCE P ANTAGONIST;

ADULT; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEALKYLATION; DEHYDROGENATION; DERIVATIZATION; DRUG EXCRETION; DRUG METABOLISM; FECES; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; RADIOACTIVITY; REACTION ANALYSIS; SINGLE DRUG DOSE; URINE;

ADMINISTRATION, ORAL; ADULT; ANALYTIC SAMPLE PREPARATION METHODS; ANTIEMETICS; BENZYLAMINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DANSYL COMPOUNDS; DEALKYLATION; FECES; HUMANS; HYDROXYLATION; MALE; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; RECEPTORS, NEUROKININ-1; REFERENCE VALUES; TANDEM MASS SPECTROMETRY;

EID: 34250700018     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015362     Document Type: Article

References (23)

1. Diemunsch P and Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533-546.
2. Domanski DL, Finta C, Halpert JR, and Zaphiropoulos PG, (2001) cDNA cloning and initial characterization of cYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392.
3. Evangelista S (2001) Ezlopitant. Pfizer. Curr Opin Investig Drugs 2:1441-1443.
4. Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan R, Mason J, and Meisenberg BR (1997) An all oral antiemetic regimen for patients undergoing high-dose chemotheraphy with peripheral blood stem transplant. Bone Marrow Transplant 20:473-478.
5. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, and Ward P (1996) GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Eur J Pharmacol 65:45-53.
6. Gonsalves SF, Watson JW, and Ashton CA (1996) Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305:181-185.
7. Grélot L, Dapzol J, Esteve E, Frugiere A, Bianchi AL, Sheldrick RL, Gardner CJ, and Ward P (1998) Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol 124:1643-1650.
8. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, and Silberman SL (1999) Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974, in the control of cisplatin-induced emesis. J Clin Oncol 17:338-343.
9. Ishida T, Matsumoto T, Caldwell J, and Drake A (1998) Enantioselective biotransformation of ary-isopropyl, -isopropenyl, and -propenyl groups by the rabbit or by the rat. Enantiomer 3:133-147.
10. Johnson K and Prakash C (2005) Metabolism, excretion and pharmacokinetics of (3-{[4-tertbutyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)- acetic acid, an EP-2 receptor selective pge2 agonist, in the rat. Drug Metab Dispos 33:1191-1201.
11. Kamel A and Prakash C (2006) High performance liquid chromatography/ atmospheric pressure ionization/tandem mass spectrometry (HPLC/API/MS/MS) in drug metabolism and toxicology studies. Curr Drug Metab 7:837-852.
12. Kamel A, Prakash C, Saverino C, Obach B, and Fouda H (2000) Narrow-bore high-performance liquid chromatography in combination with ionspray tandem mass spectrometry for the determination of the substance P receptor antagonist ezlopitant and its two active metabolites in plasma. J Chromatogr B Biomed Sci Appl 748:179-188.
13. Li AP, Kaminsky DL, and Rasmussen A (1995) Substrate of human hepaticcytochrome P450 3A4. Toxicology 104:1-8.
14. Obach RS (2000) Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 28:1069-1076.
15. Obach RS (2001) Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. Drug Metab Dispos 29:1057-1067.
16. Reed-Hagen AE, Tsuchiya M, Shimada K, Wentland J-A, and Obach RS (1999) Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites. Biopharm Drug Dispos 20:429-439.
17. Roila F (1996) Control of acute cisplatinum-induced emesis over repeat course of chemotherapy. Oncology 53 (Suppl 1):65-72.
18. Tsuchiya M, Fujiwara Y, Kanai Y, Mizutani M, Shimada K, Suga O, Ueda S, Watson JW, and Nagahisa A (2002) Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret. Pharmacology 66:144-152.
19. Tsuchiya M, Sakakibara A, and Yamamoto M (2005) a tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behavior in the rat. Eur J Pharmacol 507(1-3):29 -34.
20. Watson JW, Gonsalves SF, and Fossa AA (1995a) The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115:84-94.
21. Watson JW, Nagahisha A, and Lucot JB (1995b) The tachykinins and emesis: toward complete control, in Serotonin and the Scientific Basis of Anti-emetic Therapy (Reynolds DJM, Andrew PLR, and Davis CJ eds) pp 233-238. Oxford Clinical Communications, Oxford, UK.
22. Wrighton SA, VandenBranden M, and Ring, B. J., (1996), The human drug metabolizing cytochrome P450. J Pharmacokinet Biopharmacol 24:461-473.
23. 14C]CJ-11,972-01, in Isotope Production and Applications in the 21st Century. Proceedings of the 3rd International Conference on Isotopes, Vancouver, BC, Canada, 6-10 September, 1999 (Stevenson NR ed), pp 400-402. TRIUMF, Vancouver.